Register Login

PLASTIC RECONSTRUCTIVE AND REGENERATIVE SURGERY

Abstract

Over the past years, SARS-CoV-2 has shown a worrisome tendency for immune escape mutations. Up until now, this development has culminated in the emergence of SARS-CoV-2 ‘Omicron’ variants. Indeed, monoclonal antibody drugs which had previously been effective and thus approved for COVID-19 treatment are ineffective in neutralizing the currently circulating ‘Omicron’ virus strains. This is remarkably different for polyclonal immunoglobulin (IG) preparations that are manufactured from plasma of thousands of COVID-19 convalescent and/or vaccinated donors: In the present study, it is shown that the neutralizing potency of currently released IG lots against ‘Omicron’ is still in a range for which successful treatment of COVID-19 in hospitalized (i.e., symptomatic) immunocompromised patients has been proposed. Consequentially, for a prophylactic situation – the typical setting of immunodeficient patients receiving periodic IG infusions –, it can be anticipated that the effectiveness of current IG lots is even more promising.

Downloads

pdf
Authors

David McIntosh - UK Plasma Action, Petersfield, United Kingdom

Thierry Burnouf - UK Plasma Action, Petersfield, United Kingdom; Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan; International PhD Program in Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan https://orcid.org/0000-0002-0507-9243

Michael Karbiener - Global Pathogen Safety, Takeda Manufacturing Austria AG, Vienna, Austria https://orcid.org/0000-0002-8064-2489

Maria R. Farcet - Global Pathogen Safety, Takeda Manufacturing Austria AG, Vienna, Austria https://orcid.org/0000-0002-2335-8609

Thomas R. Kreil - Global Pathogen Safety, Takeda Manufacturing Austria AG, Vienna, Austria https://orcid.org/0000-0001-9970-0987

  • Abstract viewed - 768 times
  • pdf downloaded - 192 times